Serious question, so please don’t jump at me.
invested in biotechs, looked at this back when 22c as patient recruitment seemed promising, however the amount of money execs & board were paying themselves and lack of skin in game by CEO had me stopping any buy orders right there and then.
Has Michelle got any skin in the game yet? Put her money where her mouth is?
Ann: Opyl - Business Update & Appendix 4C, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.072M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63192 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 6000 | 1 |
View Market Depth
| Last trade - 16.12pm 18/10/2024 (20 minute delay) ? |
| OPL (ASX) Chart |
Day chart unavailable